CD8A and neoplasm: Our results showed that compared with recipient mice that received WT CD8+ T cells from mice bearing B16-F10 tumors, those that received WT CD8+ T cells from mice bearing MC38 tumors exhibited similar tumor inhibition in primary tumors but more potent tumor regression in distant tumors (Figure 4B, C and Figure S7A, B).